Author Index

VOLUME 22, 2001

Battistella, Felix D., 627
Baumann, Michael H., 647
Bernard, Gordon R., 293
Boehler, Annette, 509
Brophy, Gretchen M., 211
Brown, Kevin K., 399

Caironi, Pietro, 259
Carlet, Jean M., 51
Collard, Harold R., 347
Cooper, Andrew B., 153
Cullinan, Paul, 461

De Backer, Daniel, 61
de Campos, José Ribas Milanez, 665
Dellinger, R. Phillip, 1
Demedts, Maurits, 435
Doelken, Peter, 631
Doerr, Clinton H., 617
du Bois, R. M., 345, 387

Elkin, S. L., 387
Ely, E. Wesley, 115
Epstein, Scott K., 137

Ferrer, Jaume, 637
Filho, Laert Oliveira Andrade, 665
Filomeno, Luiz Tarcísio Brito, 665
Flaherty, Kevin R., 357, 423, 517
Fraser, Gilles L., 189
Furuya, Yu, 3

Gabor, Jonathan Y., 153
Gaine, Sean P., 533
Gattinoni, Luciano, 259
Gay, Steven E., 517
Gehr, Lynne C., 175
Grap, Mary Jo, 211
Grimminger, Friedrich, 247
Günther, Andreas, 247

Hall, Jesse B., 199, 235
Hanly, Patrick J., 153
Heffner, John E., 591
Hendel, Robert C., 75
Himes, Daniel, 35
Hlatky, Roman, 3
Holmes, Cheryl L., 307
Hudson, Leonard D., 327

Inouye, Sharon K., 115
Iregui, Manuel G., 317
Iteld, Lawrence, 13

Jacoby, Robert C., 627
Jastremski, Connie A., 89
Jatene, Fabio Biscegli, 665

Kelley, Mark A., 95
Kempainen, Robert R., 675
King, Talmadge E., Jr., 347
Klein, Jeffrey, 591
Kollef, Marin H., 317
Kotloff, Robert, 489
Kress, John P., 199, 281

Lake, Kathleen D., 559
Lang, John D., Jr., 127
Latenser, Barbara A., 13
Lee, Catherine M., 327
Lee, Warren L., 269
Light, Richard W., 657
Lipschik, Gregg Y., 95
Lynch, Joseph P., III, 345, 357, 423, 517

Marini, John J., 281
Martin, Greg S., 293
Martinez, Fernando J., 357, 423, 477, 489, 517
Maurer, Janet R., 499
McArdle, Philip, 127
Miller, Daniel L., 617

Nasraway, Stanley A., Jr., 165
Neff, Margaret J., 237
Nemery, Benoit, 435
Nicholson, Andrew G., 387, 409

Orens, Jonathan B., 477, 533

Pandulo, Fernando Luiz, 665
Pelosi, Paolo, 259
Pierson, David J., 675

Raghu, Ganesh, 357
Riker, Richard R., 189
Roberts, Pamela R., 29
Robertson, Claudia S., 3
Rouhani, Mazyar, 35
Rubenfeld, Gordon D., 237
Ryu, Jay H., 617

Sahn, Steven A., 589, 607, 631
Sanders, K. David, 127
Schmidt, Gregory A., 235
Schwarz, Marvin I., 399
Seeger, Werner, 247
Sessler, Curtis N., 109, 111, 175, 211
Siegel, M[illegible] D., 115
Slovis, Corey M., 35
Slutsky, Arthur S., 269
Snell, Gregory I., 541

Travis, William, 357, 423
Trulock, Elbert P., 479

Valadka, Alex B., 3
Verbeken, Erik K., 435
Verleden, Geert M., 551
Vincent, Jean-Louis, 61
Vourlekis, Jason S., 399

Walley, Keith R., 307
Walmrath, Dieter, 247
Wells, Athol U., 449
Werebe, Eduardo de Campos, 665
White, Eric S., 357, 517
White, Steven J., 35
Williams, Trevor J., 541
Wurfel, Mark, 357

Zimmerman, Janice L., 1, 23

Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

Subject Index

VOLUME 22, 2001

Activated charcoal, multiple dose administration, toxicology management, 23–27
Acute allograft rejection. *See also* Rejection therapy
  immunosuppressive drugs and therapeutic strategies for, 559–575
Acute care nurse practitioners (ACNPs), care of intensive care unit (ICU) patients, 89–93
Acute coronary syndrome (ACS), antithrombotic/reperfusion therapy, 75–85
Acute interstitial pneumonitis (AIP), diagnosis, pathogenesis and natural history, 399–405
Acute lung injury (ALI)
  epidemiology, 237–244
  pathophysiology, 247–256, 293–302
Acute pancreatitis, nutritional therapy, 29–33
Acute respiratory distress syndrome (ARDS)
  acute interstitial pneumonitis (AIP), 399–405
  cardiovascular management, 307–314
  epidemiology, 237–244
  long-term outcomes, 327–335
  lung-protective ventilation adjuncts, 281–289
  mechanical ventilation, 269–279
  pathophysiology, 247–256, 293–302
  pulmonary and extrapulmonary forms of, 259–266
  therapeutic innovations, 293–302
  ventilator-associated pneumonia and, 317–323
Acute respiratory failure (ARF)
  fibrotic lung disease, lung transplant, timing, 523–527
  malignant pleural effusions, 607–613
Adrenergic agents, sepsis-induced organ hypoperfusion, inotrope/vasopressor support, 61–69
Adrenergic agonists, sedatives in ICU patients, 169–172
Aerosolized cyclosporine, acute/chronic allograft rejection therapy, 574–575
Aging patients, organ dysfunction syndrome, delirium with, 115–124
Agitation, monitoring in ICU patients, 189–196
Air leaks, mechanical ventilation in patients and, 675–682
Alpha-agonists, cardiopulmonary resuscitation (CPR), controversies concerning, 43–46
Aminophylline, cardiopulmonary resuscitation (CPR), controversies concerning, 43–46
Amiodarone, cardiopulmonary resuscitation (CPR), controversies concerning, 35–46
Analgesics
  cost-effectiveness, in ICU patients, 199–207
  monitoring in ICU patients, 189–196
  multidisciplinary management in critical care, 211–222
  organ dysfunction syndrome, delirium with, 115–124
  pain management in ICU patients, 127–134
Antibiotics
  critical care management and, 51–58
  resistance, in critically ill patients, 51–58
Anticoagulants, antithrombotic and reperfusion therapies, 75–85
Antimicrobial impregnated central venous catheters, antibiotics management, 54–58
Antiplatelet therapies, antithrombotic and reperfusion therapies, 75–85
Antithrombotic therapy, acute myocardial infarction/ischemia, 75–85
Antithymocyte globulin (ATG), acute/chronic allograft rejection therapy, 559–575
Arterial blood gas analysis, acute respiratory distress syndrome (ARDS), long-term outcomes, 330–335
Atelectasis, ventilator-induced lung injury (VILI) and, 269–279

Barotrauma
  lung-protective ventilation adjuncts, 281–289
  mechanical ventilation in patients, air leaks and, 675–682
  ventilator-induced lung injury (VILI), 269–279
Benzodiazepines
  cost-effectiveness in ICU patients, 199–207
  in ICU patients, 165–172
Bicarbonate, cardiopulmonary resuscitation (CPR), controversies concerning, 39–46
Bilateral lung transplantation (BLT)
  chronic obstructive pulmonary disease (COPD), 489–496
  cystic fibrosis patients, lung transplant selection, timing and outcome, 503–506
Biotrauma, ventilator-induced lung injury (VILI), 269–279
Blood alkalinization, toxicology management, 23–27
Brain injury, cerebral perfusion pressure (CPP) management, 3–10
Bretylium, cardiopulmonary resuscitation (CPR), controversies concerning, 46
Bronchiectasis, cystic fibrosis patients, lung transplant evaluation and, 499–506
Bronchiolitis obliterans organizing pneumonia (BOOP)
  chronic allograft rejection, 551–555
  diagnosis and classification, 449–457
Bronchoalveolar lavage (BAL)
  idiopathic interstitial pneumonia (IIP) histopathology, 351–354

Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

Bronchoalveolar lavage (BAL) *(cont.)*
idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonia with, 367–377
Bronchopleural fistula (BPF), mechanical ventilation in patients and, 675–682
Bronchoscopy, acute respiratory distress syndrome (ARDS) complication and, 317–323
Burn injuries, smoke inhalation, 13–21

Capnography, cardiopulmonary resuscitation (CPR), controversies concerning, 35–46
Carbon monoxide toxicity, smoke inhalation injury, 13–21
Cardiac arrest, cardiopulmonary resuscitation (CPR), controversies concerning, 35–46
Cardiac output, acute respiratory distress syndrome (ARDS) management and, 307–314
Cardiopulmonary interaction, acute respiratory distress syndrome (ARDS) management and, 307–314
Cardiopulmonary resuscitation (CPR), controversies in management of, 35–46
Cardiovascular system, acute respiratory distress syndrome (ARDS) management and, 307–314
Catheterization, antimicrobial impregnated central venous catheters, 54–58
Cerebral blood flow, cerebral perfusion pressure (CPP) management, 3–10
Cerebral ischemia, cerebral perfusion pressure (CPP) management, 3–10
Cerebral perfusion pressure (CPP), management strategies, 3–10
Chest radiography, idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonia with, 362–377
Chronic allograft rejection. *See also* Rejection therapy
immunosuppressive drugs and therapeutic strategies for, 559–575
lung and heart-lung transplantation, 551–555
Chronic obstructive pulmonary disease (COPD), lung transplantation implications, 489–496
Chylous pleural effusion, diagnosis and management, 617–624
Circulatory shock, sepsis-induced organ hypoperfusion, inotrope/vasopressor support, 61–69
Coagulation, acute respiratory distress syndrome (ARDS), pathophysiology, 247–256
Cobalt exposure, giant cell interstitial pneumonia, 435–444
Cognitive impairment
acute respiratory distress syndrome (ARDS), long-term outcomes, 332–335
organ dysfunction syndrome, delirium with, 115–124
Collagen vascular disease, lung transplant, timing, 517–527
Computed tomography (CT), acute respiratory distress syndrome (ARDS), pulmonary/extrapulmonary forms, 259–266
Coronary artery bypass graft (CABG) surgery, pleural effusions, 657–662
Coronary artery disease, antithrombotic and reperfusion therapies, 75–85
Corticosteroids
acute/chronic allograft rejection therapy, 574–575
acute respiratory distress syndrome (ARDS) therapy, 293–302
idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonia therapy, 371–377
Cost-effectiveness
critical care delivery, 95–99
sedation, analgesia, and neuromuscular blockade, ICU patients, 199–207
Critical care management
antibiotics management, 51–58
care delivery models, 95–99
cost-effectiveness of sedation, analgesia and neuromuscular blockade in ICU patients, 199–207
multidisciplinary approach to sedation and analgesia, 211–222
by nonphysician clinicians (NPCs), 89–93
organ dysfunction syndrome, delirium with, 115–124
sleep management, 153–162
Cryptogenic fibrosing alveolitis (CFA)
lung transplant, timing, 517–527
usual interstitial pneumonia (UIP), 357–377
Cryptogenic organizing pneumonia (COP), diagnosis and classification, 449–457
Cyanide toxicity, smoke inhalation injury, 14–21
Cyclic antidepressants. *See also* Tricyclic antidepressants (TCA)
toxicology management, 23–27
Cyclooxygenase, acute respiratory distress syndrome (ARDS) therapy, 293–302
Cyclothorax, diagnosis and management, 617–624
Cystic fibrosis, lung transplantation, patient selection, timing, and outcome, 499–506
Cytokines
acute/chronic allograft rejection therapy, 559–575
acute respiratory distress syndrome (ARDS) pathophysiology, 247–256
acute respiratory distress syndrome (ARDS) therapy, 293–302

Delirum
monitoring in ICU patients, 189–196
organ dysfunction syndrome, 115–124
Dermatomyosis, fibrotic lung disease, lung transplant, timing, 525–527
Desquamative interstitial pneumonia (DIP), respiratory bronchiolitis-associated interstitial lung disease (RBILD), 387–395
Dexmedetomidine, in ICU patients, 165–172
Diabetic ketoacidosis (DKA), cardiopulmonary resuscitation (CPR), controversies concerning, 41–46
Diagnostic techniques
acute lung injury (ALI), 237–244
desquamative interstitial pneumonia (DIP), classification, 387–395
interstitial pneumonia, histopathologic subgroups, lung biopsy, 347–354
Diamond dust exposure, giant cell interstitial pneumonia, 435–444
Diet and nutrition, acute pancreatitis, nutritional alteration, 32–33
Diffuse alveolar damage (DAD), acute interstitial pneumonitis (AIP), 399–405
Dobutamine, organ failure, 61–69

Donor management, organ procurement and optimization strategies, 541–549
Dopamine, arterial pressure management, 61–69

Emphysema, pneumothorax classification and management, 647–653
Empyema
  hemothorax diagnosis and management, 627–629
  management of, 591–602
  tubercular, 637–643
Endotoxins, acute respiratory distress syndrome (ARDS) therapy, 293–302
Endotracheal tube (ETT) location, cardiopulmonary resuscitation (CPR), controversies concerning, 35–46
End-stage respiratory disease
  cystic fibrosis patients, lung transplant selection, timing and outcome, 503–506
  cystic lung disease, lung transplantation, 509–514
  pulmonary hypertension, lung transplantation, 533–539
End-tidal CO_2 ($ETCO_2$), cardiopulmonary resuscitation (CPR), controversies concerning, 35–46
Enteral nutrition, acute pancreatitis therapy, 29–33
Environmental factors, idiopathic interstitial pneumonia, 461–466
Eosinophilic granuloma, lung transplantation, 509–514
Epidemiologic studies
  acute lung injury (ALI), 237–244
  idiopathic interstitial pneumonia, 461–466
Epinephrine, cardiopulmonary resuscitation (CPR), controversies concerning, 35–46
Extracorporeal gas exchange, lung-protective ventilation adjuncts, 281–289
Extracorporeal life support (ECLS), smoke inhalation injury, 19–21
Extrapulmonary pneumonia, acute respiratory distress syndrome (ARDS), 259–266

Fibroblastic foci, idiopathic pulmonary fibrosis (IPF) lesions, 357–377
Fibroblasts, idiopathic pulmonary fibrosis (IPF) lesions, 357–377
Fibrosis
  idiopathic pulmonary fibrosis (IPF), 357–377
  pathophysiology, 247–256
Fibrotic lung disease, lung transplant timing, 517–527
Follicular bronchiolitis, lymphocytic interstitial pneumonia (LIP), differential diagnosis, 409–418
Follow-up studies, acute respiratory distress syndrome (ARDS), long-term outcomes, 327–335
Full-time critical care teams, critical care delivery models, 95–99

Gastric lavage, toxicology management, 23–27
Gastric tonometry, sepsis-induced organ hypoperfusion, inotrope/vasopressor support, 61–69
Geriatrics, organ dysfunction syndrome, delirium with, 115–124
Giant cell interstitial pneumonia (GIP)
  differential diagnosis, 435–444
  fibrotic lung disease, lung transplant, timing, 526–527

Hamman-Rich syndrome, acute interstitial pneumonitis (AIP), 399–405
Hard metal lung disease. See Giant cell interstitial pneumonia (GIP)
Head injury, cerebral perfusion pressure (CPP) management, 3–10
Heart-lung transplantation
  chronic allograft rejection, 551–555
  results assessment, 479–487
Hemodynamic stabilization, adrenergic agents for, 61–69
Hemothorax, diagnosis and management, 627–629
Hepatic hydrothorax, pathophysiology and management, 665–672
High resolution computed tomography (HRCT), idiopathic interstitial pneumonia (IIP) histopathology, 351–354
Histiocytosis X, lung transplantation, 509–514
Histopathologic analysis, idiopathic interstitial pneumonia (IIP), 347–354
Honeycombing, idiopathic pulmonary fibrosis (IPF) lesions, 357–377
Hospital-acquired pneumonia (HAP), acute respiratory distress syndrome (ARDS) complicated with, 317–323
Hyperbaric oxygen therapy, smoke inhalation injury, 17–21
Hypercapnia, lung-protective ventilation adjuncts, 281–289
Hypoperfused septic patients, inotrope/vasosuppressor support, 61–69

Iatrogenic pneumothorax, classification and management, 647–653
Idiopathic interstitial pneumonia (IIP)
  desquamative interstitial pneumonia (DIP), classification, 387–395
  environmental triggers, 461–466
  fibrotic lung disease, lung transplant, timing, 523–527
  histopathologic subgroups, lung biopsy, 347–354
  nonspecific interstitial pneumonia (NSIP), differential diagnosis, 423–432
Idiopathic pulmonary fibrosis
  idiopathic interstitial pneumonia, environmental triggers, 461–466
  lung transplant, timing, 517–527
  usual interstitial pneumonia (UIP) with, 357–377
Immunosuppressive therapy, acute/chronic allograft rejection and, 559–575
Incidence studies, acute lung injury (ALI), 237–244
Inotrope/vasopressor support, sepsis-induced organ hypoperfusion, 61–69
Intensive care unit (ICU) patients
  antibiotics management, 51–58
  comfort and distress issues, 111–112
  cost-effectiveness of sedation, analgesics and neuromuscular blocking agents (NMBA), 199–207
  critical care delivery models, 95–99
  delirium and organ dysfunction, 115–124
  multidisciplinary approach to sedation and analgesia, 211–222
  neuromuscular blockade, 175–186
  nonphysician clinicians in, 89–93
  pain management, 127–134

Intensive care unit (ICU) patients *(cont.)*
sedation, agitation, analgesic, neuromuscular blockade, and delirium monitoring in, 189–196
sedative medications for, 165–172
sleep disruption in, 153–162
Intensivists
critical care delivery, 95–99
organ dysfunction syndrome, delirium with, 115–124
Interferon therapy, idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonia (UIP), 375–377
Interleukin antagonists, acute/chronic allograft rejection therapy, 559–575
Interstitial lung disease, lung transplant, timing, 517–527
Interstitial pneumonia
desquamative, 387–395
giant cell interstitial pneumonia (GIP), 435–444
histopathologic subgroups, clinical significance, 347–354
idiopathic (IIP), 461–466
lymphocytic, 409–418
nonspecific (NSIP), 423–432
usual interstitial pneumonia (UIP) diagnosis, 357–377
Intracranial hemorrhage, cerebral perfusion pressure (CPP) management, 3–10
Intrapleural fibrinolysis, parapneumonia effusion, management strategies, 591–602
Ischemia
cerebral ischemia, cerebral perfusion pressure (CPP) management, 3–10
myocardial, antithrombotic and reperfusion therapies, 75–85
myocardial, pain management in ICU patients, 127–134

Ketamine, pain management in ICU patients, 131–134
Ketorolac, pain management in ICU patients, 132–134

Lactic acidosis, bicarbonate administration, cardiopulmonary resuscitation (CPR), controversies concerning, 42–46
Lidocaine, cardiopulmonary resuscitation (CPR), controversies concerning, 45–46
Lipid metabolism, chylous pleural effusion, diagnosis and management, 617–624
Lithium overdose, toxicology management, 23–27
Living donor transplants, cystic fibrosis patients, lung transplant selection, timing and outcome, 503–506
Lung biopsy
idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonia with, 360–377
interstitial pneumonia, histopathologic subgroups, clinical significance, 347–354
Lung-protective ventilation adjuncts, acute respiratory distress syndrome (ARDS), 281–289
Lung transplantation
chronic allograft rejection, 551–555
chronic obstructive pulmonary disease (COPD), implications of, 489–496
cystic fibrosis patients, selection, timing and outcome, 499–506
cystic lung diseases, 509–514
fibrotic lung disease, timing considerations, 517–527
organ procurement and optimization strategies, 541–549
pulmonary hypertension, 533–539
rejection, immunosuppressive drugs and therapeutic strategies for, 559–575
results assessment, 479–487
Lymphangioleiomyomatosis, lung transplantation, 509–514
Lymphocytic interstitial pneumonia (LIP), differential diagnosis, 409–418
Lymphoproliferative disorders, lymphocytic interstitial pneumonia (LIP), differential diagnosis, 409–418

Malignant pleural effusions, management strategies, 607–613
Mechanical ventilation
air leaks, management of, 675–682
cost-effectiveness of sedation, analgesia and neuromuscular blockade in ICU patients, 201–207
organ dysfunction syndrome, delirium with, 115–124
patient-ventilator synchronization, 137–148
ventilator-induced lung injury (VILI) and acute respiratory distress syndrome (ARDS), 269–279
Mixed connective tissue disease (MCTD), fibrotic lung disease, lung transplant, timing, 526–527
Mortality rates. *See also* Survival studies
acute lung injury (ALI), 243–244
Mucosa-associated lymphoid tissue (MALT) lymphoma, lymphocytic interstitial pneumonia (LIP), differential diagnosis, 409–418
Multiple-dose activated charcoal, toxicology management, 23–27
Multiple organ failure
acute respiratory distress syndrome (ARDS) management and, 307–314
sepsis-induced organ hypoperfusion, inotrope/vasopressor support, 61–69
Myocardial infarction
antithrombotic and reperfusion therapies, 75–85
pain management in ICU patients, 127–134

Neuromuscular blocking agents (NMBA)
cost-effectiveness, in ICU patients, 199–207
intensive care unit (ICU) patients, 175–186
monitoring in ICU patients, 189–196
Nitric oxide, lung-protective ventilation adjuncts, 281–289
Nonphysician clinicians (NPCs), care of intensive care unit (ICU) patients, 89–93
Nonspecific interstitial pneumonia (NSIP)
differential diagnosis, 423–432
lung transplant, timing, 517–527
Norepinephrine, arterial pressure management, 61–69
Nosocomial infection, acute respiratory distress syndrome (ARDS) complication and, 317–323
Nutritional therapy, acute pancreatitis management, 29–33

Obliterative bronchiolitis (OB)
chronic allograft rejection and, 551–555
immunosuppressive drugs and therapeutic strategies for, 559–575
Occupational safety and health
fibrotic lung disease, lung transplant, timing, 526–527
giant cell interstitial pneumonia (GIP), 435–444
idiopathic interstitial pneumonia, environmental triggers, 461–466

OKT3 (murine monoclonal antibody, OKT3), acute/chronic allograft rejection therapy, 559–575
Opiates, cost-effectiveness in ICU patients, 199–207
Organ allocation protocols
  lung and heart-lung transplantation, results assessment, 479–487
  procurement strategies and donor availability, 541–549
Organ dysfunction syndrome, delirium in ICU patients, 115–124
Outcome-based models
  acute respiratory distress syndrome (ARDS), long-term outcomes, 327–335
  critical care delivery, 95–99
  cystic fibrosis patients, lung transplant selection, timing and outcome, 499–506
  lung and heart-lung transplantation, results assessment, 479–487
Overlap syndrome, fibrotic lung disease, lung transplant, timing, 526–527
Oxygen delivery, acute respiratory distress syndrome (ARDS) management and, 307–314

Pain management, intensive care unit (ICU) patients, 127–134
Pancreatitis, acute, nutritional support for management of, 29–33
Paralysis, neuromuscular blocking agents, intensive care unit (ICU) patients, 175–186
Parapneumonic effusion, management of, 591–602
Parenchymal-pleural fistula (PPF), mechanical ventilation in patients, air leaks and, 675–682
Patient-ventilator interaction, optimal synchronization, 137–148
Perflubron, lung-protective ventilation adjuncts, 281–289
Peripheral nerve stimulation, neuromuscular blocking agents, intensive care unit (ICU) patients, 175–186
Pharmacokinetics
  acute/chronic allograft rejection therapy, 559–575
  antibiotics management, 51–58
  pain management in ICU patients, 130–134
  sedatives in ICU patients, 165–172
Physician assistants (PAs), care of intensive care unit (ICU) patients, 89–93
Pirfenidone, idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonia (UIP) therapy, 375–377
Pleural decortication
  hemothorax diagnosis and management, 627–629
  trapped lung management, 631–635
Pleural drainage, hepatic hydrothorax diagnosis and management, 665–672
Pleural effusions
  cyclothorax, 617–624
  malignant effusions, 607–613
  parapneumonia effusion, management strategies, 591–602
  post-cardiac injury/coronary artery bypass surgery, 657–662
  tubercular, 637–643
Pleural fluid pH, malignant pleural effusions, 607–613
Pleural pressure, trapped lung and, 631–635
Pleural space elastance, trapped lung and, 631–635
Pleurodesis
  hepatic hydrothorax, 665–672
  malignant pleural effusions, 607–613
Pneumonia
  acute respiratory distress syndrome (ARDS) complicated with, 317–323
  cryptogenic organizing, 449–457
  extrapulmonary, acute respiratory distress syndrome (ARDS), 259–266
  fibrotic lung disease, lung transplant, timing, 517–527
  giant cell interstitial, 435–444
  interstitial, histopathologic subgroups, 347–354
  interstitial desquamative, 387–395
  lymphocytic interstitial, 409–418
  nonspecific interstitial (NSIP), 423–432
  parapneumonia effusion, management strategies, 591–602
  usual interstitial, diagnosis, 357–377
Pneumonitis, acute interstitial, 399–405
Pneumothorax
  classification and management, 647–653
  mechanical ventilation in patients and, 675–682
Polymyositis, fibrotic lung disease, lung transplant, timing, 525–527
Polysomnography, sleep disruption in critically ill patients, 153–162
Positive end-expiratory pressure (PEEP)
  acute respiratory distress syndrome (ARDS), 259–266
  ventilator-induced lung injury (VILI), 269–279
Post-cardiac injury (Dressler's) syndrome (PCIS), pleural effusions, 657–662
Posttraumatic stress disorder (PTSD), acute respiratory distress syndrome (ARDS), long-term outcomes, 333–335
Pressure-volume curve, ventilator-induced lung injury (VILI) and, 269–279
Prevalence studies, acute lung injury (ALI), 237–244
Primary spontaneous pneumothoraces (PSP), classification and management, 647–653
Prognostic studies
  chronic obstructive pulmonary disease, lung transplantation prognostication, 489–496
  cryptogenic organizing pneumonia (COP), 449–457
  cystic fibrosis patients, lung transplant selection, timing and outcome, 499–506
Prolonged paralysis, neuromuscular blocking agents, intensive care unit (ICU) patients, 175–186
Prone positioning, lung-protective ventilation adjuncts, 281–289
Propofol, in ICU patients, 165–172
Prostacyclin therapy, pulmonary hypertension, lung transplantation, 533–539
Pulmonary dysfunction, pain management in ICU patients, 127–134
Pulmonary fibrosis
  acute interstitial pneumonitis (AIP), 399–405
  idiopathic, 357–377
Pulmonary function testing
  acute respiratory distress syndrome (ARDS), long-term outcomes, 330–335
  idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonia with, 362–377
Pulmonary hygiene, smoke inhalation injury, 13–21

Pulmonary hypertension, lung transplantation, 533–539
Pulmonary pneumonia, acute respiratory distress syndrome (ARDS), 259–266

QRS complex, toxicology management, blood alkalinization, 27
Quality of life issues, acute respiratory distress syndrome (ARDS), long-term outcomes, 327–335

Ramsay scale, sedation/agitation monitoring in ICU patients, 190–196
Rapid eye movement (REM) sleep, in intensive care unit (ICU) patients, 153–162
Recruitment-derecruitment, mechanism, ventilator-induced lung injury (VILI) and, 269–279
Rejection therapy. *See also* Acute and Chronic rejection
  chronic allograft rejection, management, 551–555
  immunosuppressive therapy, acute/chronic rejection, 559–575
Reperfusion therapy, acute myocardial infarction/ischemia, 75–85
Respiratory bronchiolitis-associated interstitial lung disease (RBILD), desquamative interstitial pneumonia (DIP), 387–395
Respiratory diseases, organ dysfunction syndrome, delirium with, 115–124
Respiratory function, patient-ventilator synchronization, 137–148
Rheumatoid arthritis, fibrotic lung disease, lung transplant, timing, 525–527
Riker sedation-agitation scale (SAS), sedation/agitation monitoring in ICU patients, 190–196

Sarcoidosis, lung transplantation, 509–514
Scleroderma, fibrotic lung disease, lung transplant, timing, 524–527
Secondary spontaneous pneumothoraces (SSP), classification and management, 647–653
Sedatives
  cost-effectiveness, in ICU patients, 199–207
  in ICU patients, 165–172
  monitoring in ICU patients, 189–196
  multidisciplinary management in critical care, 211–222
  organ dysfunction syndrome, delirium with, 115–124
Selective digestive decontamination (SDD), antibiotics management, 51–58
Sepsis, acute respiratory distress syndrome (ARDS) therapy, 293–302
Sepsis-induced organ hypoperfusion, inotrope/vasopressor support, 61–69
Severe infection, antibiotics management, 51–58
Single lung transplantation (SLT), chronic obstructive pulmonary disease (COPD), 489–496
Sirolimus (SRL) antagonists, acute/chronic allograft rejection therapy, 559–575
Sjogren's syndrome, fibrotic lung disease, lung transplant, timing, 526–527
Sleep disruption, critically ill patients, 153–162
Smoke inhalation injury, ventilatory management, 13–21
Smoking, idiopathic interstitial pneumonia, environmental triggers, 461–466
Sodium polystyrene sulfate (SPS), toxicology management, 26
Splanchnic circulation, sepsis-induced organ hypoperfusion, inotrope/vasopressor support, 61–69
Spontaneous pneumothorax (SP), classification and management, 647–653
Staffing policies, critical care delivery models, 95–99
Surfactants
  acute respiratory distress syndrome (ARDS), pathophysiology, 247–256
  acute respiratory distress syndrome (ARDS) therapy, 293–302
  lung-protective ventilation adjuncts, 281–289
Survival studies. *See also* Mortality rates; Outcome-based models; Prognostic studies
  chronic obstructive pulmonary disease, lung transplantation prognostication, 489–496
  cryptogenic organizing pneumonia (COP), 449–457
Systemic inflammatory response syndrome (SIRS), acute pancreatitis, nutritional alteration, 31–33
Systemic lupus erythematosis, fibrotic lung disease, lung transplant, timing, 526–527

Talc pleurodesis, malignant pleural effusions, 607–613
Talc poudrage, hepatic hydrothorax diagnosis and management, 665–672
Therapeutic strategies
  acute/chronic allograft rejection, 559–575
  acute pancreatitis management, 29–33
  acute respiratory distress syndrome (ARDS), 293–302
  antithrombotic/reperfusion therapies, 75–85
  chronic obstructive pulmonary disease, lung transplantation prognostication, 489–496
  cystic lung diseases, lung transplants, 509–514
  idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonia (UIP), 3710377
  pulmonary hypertension, lung transplantation, 533–539
  smoke inhalation injury, 17–21
Thoracentesis
  malignant pleural effusions, 607–613
  post-cardiac injury/surgery pleural effusions, 657–662
Thoracoscopy, hepatic hydrothorax diagnosis and management, 665–672
Thrombolysis, antithrombotic and reperfusion therapies, 75–85
Total lymphoid irradiation (TLI), acute/chronic allograft rejection therapy, 559–575
Total parenteral nutrition (TPN), acute pancreatitis therapy, 29–33
Toxicology, management issues, 23–27
Tracheal gas insufflation (TGI), lung-protective ventilation adjuncts, 284–289
Transbronchial biopsy (TBB), idiopathic interstitial pneumonia (IIP) histopathology, 351–354
Transjugular intrahepatic portosystemic shunt (TIPS), hepatic hydrothorax diagnosis and management, 665–672
Transplantation
  chronic allograft rejection, 551–555
  chronic obstructive pulmonary disease (COPD), implications of, 489–496

cystic fibrosis patients, lung transplant selection, timing and outcome, 503–506
fibrotic lung disease, lung transplant timing, 517–527
lung and heart-lung, results assessment, 479–487
organ procurement strategies, 541–549
rejection, immunosuppressive drugs and therapeutic strategies for, 559–575
Trapped lung
diagnosis and management, 631–635
malignant pleural effusions, 607–613
Trauma, pneumothorax classification and management, 647–653
Tricyclic antidepressants (TCA) toxicity, cardiopulmonary resuscitation (CPR), controversies concerning, 39–46
Triggering mechanisms, patient-ventilator synchronization, 139–148
Tuberculous pleural effusion and empyema, diagnosis and management, 637–643
Tungsten carbide exposure, giant cell interstitial pneumonia, 435–444

Upper airway injuries, smoke inhalation injury, 13–21
Usual interstitial pneumonia (UIP)
desquamative interstitial pneumonia (DIP), differential diagnosis, 387–395
differential diagnosis, 357–377
fibrotic lung diseases, lung transplant, timing, 517–527
nonspecific interstitial pneumonia (NSIP), differential diagnosis, 423–432

Vasoactive agents, sepsis-induced organ hypoperfusion, 61–69
Vasopressin, cardiopulmonary resuscitation (CPR), controversies concerning, 35–46
Venous return, acute respiratory distress syndrome (ARDS) management and, 307–314
Ventilator-associated pneumonia (VAP), acute respiratory distress syndrome (ARDS) complicated with, 317–323
Ventilator-induced lung injury (VILI), mechanical ventilation for, 269–279
Ventilatory strategies
acute respiratory distress syndrome (ARDS), pathophysiology, 247–256
mechanical ventilation in patients, air leaks and, 675–682
organ dysfunction syndrome, delirium with, 115–124
patient-ventilator synchrony optimization, 137–148
smoke inhalation injury, 13–21
Ventricular fibrillation (VF), cardiopulmonary resuscitation (CPR), controversies concerning, 35–46
Video assisted thoracic surgery (VATS)
hemothorax management, 627–629
hepatic hydrothorax diagnosis and management, 665–672
Viral infection, idiopathic interstitial pneumonia, environmental triggers, 461–466
Volutrauma, ventilator-induced lung injury (VILI) and, 269–279

Whole bowel irrigation, toxicology management, 23–27